FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is used together with serotonergic psychiatric medications (2011)

Government Record · U.S. Food and Drug Administration · July 26, 2011

U.S. Food, 2011-07-26: FDA safety communication warning that methylene blue inhibits MAO-A and can precipitate serotonin syndrome when combined with SSRIs, SNRIs, MAOIs and other serotonergic drugs.

methylene blue inhibits the action of monoamine oxidase A

Safety Announcement

U.S. Food, 2011-07-26: FDA safety communication warning that methylene blue inhibits MAO-A and can precipitate serotonin syndrome when combined with SSRIs, SNRIs, MAOIs and other serotonergic drugs. Federal safety communication, 26 July 2011 (updated 20 October 2011). Verified through the Internet Archive capture 20190424012314; the live fda.gov page now returns 404. The stated mechanism is MAO-A inhibition. The communication warns especially about the 1-2 mg/kg IV dose used in parathyroid localisation. Study type: regulatory record.